Revive Therapeutics (OTCQB:RVVTF) reported that its Board authorized the grant of an aggregate 15,500,000 incentive stock options to directors, officers and consultants. The options have an exercise price of $0.05 per share and a term of five years. All options were issued under the company’s 10% rolling stock option plan and remain subject to the plan terms and Canadian Securities Exchange requirements.
Loading...
Loading translation...
Positive
15,500,000 stock options granted to align key personnel with shareholder value
Options priced at $0.05 with a five-year term may support long-term retention
Grants made under existing 10% rolling stock option plan, indicating use of an established framework
Negative
Grant of 15,500,000 options could lead to future share dilution if exercised
TORONTO, ON / ACCESS Newswire / August 14, 2026 / Revive Therapeutics Ltd. ("Revive" or the "Company") (OTCQB:RVVTF)(CSE:RVV)(Frankfurt:31R), a life sciences company focused on the research and development of therapeutics for biodefence and pandemic preparedness, today announced the Board of Directors of Revive has authorized the grant of an aggregate of 15,500,000 incentive stock options to key members of our team, including directors, officers, and consultants. The stock options have an exercise price of $0.05 per share for a period of five years. All Options were granted pursuant to the Company's 10% rolling stock option plan (the "Plan") and are subject to the terms of the Plan, the applicable grant agreement and the requirements of the CSE. These stock options are an essential component of our strategy to drive performance and incentivize excellence as we advance our corporate objectives.
About Revive Therapeutics Ltd.
Revive Therapeutics is a life sciences company focused on the research and development of therapeutics for biodefence and pandemic preparedness. For more information, visit www.revivethera.com.
What stock options did Revive Therapeutics (RVVTF) grant on August 14, 2026?
Revive Therapeutics granted an aggregate of 15,500,000 incentive stock options to directors, officers and consultants. According to Revive Therapeutics, these options are part of its 10% rolling stock option plan and aim to support its corporate objectives.
What is the exercise price and term of the new Revive Therapeutics (RVVTF) stock options?
The newly granted Revive Therapeutics stock options have an exercise price of $0.05 per share and a five-year term. According to Revive Therapeutics, all options are subject to the company’s stock option plan and CSE requirements.
Who received the 15,500,000 stock options granted by Revive Therapeutics (RVVTF)?
The 15,500,000 incentive stock options were granted to key team members, including directors, officers and consultants. According to Revive Therapeutics, these grants are intended to drive performance and incentivize excellence as it advances corporate objectives.
Under what plan were the new Revive Therapeutics (RVVTF) stock options issued?
The stock options were granted under Revive Therapeutics’ 10% rolling stock option plan. According to Revive Therapeutics, all options remain subject to the plan’s terms, the specific grant agreements and the requirements of the Canadian Securities Exchange.
How could the 15,500,000 Revive Therapeutics (RVVTF) options affect shareholders?
If exercised, the 15,500,000 options at $0.05 per share may increase the company’s outstanding shares. According to Revive Therapeutics, the options are designed to align key personnel incentives with the company’s long-term corporate objectives.
Why did Revive Therapeutics (RVVTF) grant new incentive stock options in 2026?
Revive Therapeutics stated that the options are an essential component of its strategy to drive performance and incentivize excellence. According to Revive Therapeutics, this supports advancing its research and development objectives in biodefence and pandemic preparedness.
